

Eduardo L. Franco • Thomas E. Rohan
EDITORS

CANCER PRECURSORS

Epidemiology,
Detection,
and Prevention



Springer

Eduardo L. Franco, MPH, DrPH

Professor, Departments of Oncology and Epidemiology, and
Director, Division of Cancer Epidemiology, McGill University,
Montreal, Quebec, Canada

Thomas E. Rohan, MB, BS, PhD

Professor and Chairman, Department of Epidemiology and
Social Medicine, Albert Einstein College of Medicine, Bronx,
New York, USA

Editors

Cancer Precursors

Epidemiology, Detection, and Prevention

Foreword by Joseph F. Fraumeni, Jr., MD, MSc

With 50 Figures



Springer

Eduardo L. Franco, MPH, DrPH
Professor
Departments of Oncology
and Epidemiology
and
Director
Division of Cancer Epidemiology
McGill University
Montreal, Quebec H2W 1S6, Canada

Thomas E. Rohan, MB, BS, PhD
Professor and Chairman
Department of Epidemiology
and Social Medicine
Albert Einstein College
of Medicine
Bronx, NY 10461, USA

Cover illustration: For cover art, see Figure 15.1 on page 234.

Library of Congress Cataloging-in-Publication Data

Cancer precursors : epidemiology, detection, and prevention / editors, Eduardo L. Franco, Thomas E. Rohan.

p. ; cm

Includes bibliographical references and index.

ISBN 0-387-95188-1 (h/c : alk. paper)

1. Precancerous conditions. I. Franco, Eduardo L. II. Rohan, Thomas E.

[DNLM: 1. Precancerous Conditions—pathology. 2. Neoplasms—diagnosis. 3. Neoplasms—prevention & control. QZ 204 C215 2001]

RC268.5.C328 2001

616.99'4—dc21

2001049595

Printed on acid-free paper.

© 2002 Springer-Verlag New York, Inc.

All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer-Verlag New York, Inc., 175 Fifth Avenue, New York, NY 10010, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use of general descriptive names, trade names, trademarks, etc., in this publication, even if the former are not especially identified, is not to be taken as a sign that such names, as understood by the Trade Marks and Merchandise Marks Act, may accordingly be used freely by anyone.

While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Production coordinated by Chernow Editorial Services, Inc., and managed by Lesley Poliner; manufacturing supervised by Jerome Basma.

Typeset by Best-set Typesetter Ltd., Hong Kong.

Printed and bound by Maple-Vail Book Manufacturing Group, York, PA.

Printed in the United States of America.

9 8 7 6 5 4 3 2 1

ISBN 0-387-95188-1

SPIN 10789389

Springer-Verlag New York Berlin Heidelberg

A member of BertelsmannSpringer Science+Business Media GmbH

Cancer Precursors

Springer

New York

Berlin

Heidelberg

Barcelona

Hong Kong

London

Milan

Paris

Singapore

Tokyo

To Our Wives
Eliane and Rosa

Foreword

Dramatic advances in our understanding of cancer causation have come from epidemiologic and laboratory research, particularly over the past two decades. These developments have included a broadening interest in the critical events that take place during the early stages of the dynamic multistep process leading to invasive cancer. Increasingly, cancer epidemiologists are pursuing research into the origins and natural history of premalignant lesions, including intermediate or surrogate endpoints, a trend accelerated by the development of molecular technologies that are revolutionizing our understanding of the transformation of normal to malignant cells. There seems little doubt that this emerging knowledge will provide further insights not only into carcinogenic processes, but also into more sensitive methods of early detection and more effective means of prevention.

In this book, Drs. Franco and Rohan have succeeded in preparing a comprehensive, timely, and critical review of the substantial progress that has been made in our understanding of cancer precursors. They have enlisted experts in the field who have contributed authoritative chapters on the precursors to a wide variety of cancers, with emphasis on etiology and natural history, including the role of environmental and heritable factors that provoke normal cells to undergo malignant transformation. Epidemiologic data are linked whenever possible to molecular as well as classical cellular pathology, providing a fuller understanding of the causal events and mechanisms that initiate the carcinogenic process.

It is generally understood that preventing cancer is far preferable to treating it. While opportunities now exist for primary and secondary prevention of certain cancers, we are still limited by an incomplete understanding of causal factors and precursor lesions that hold the key to advances in cancer prevention. However, as a result of conceptual breakthroughs in our understanding of the fundamental mechanisms of cancer, there is growing optimism that the incorporation of molecular and genetic probes into epidemiologic and clinical approaches will more fully illuminate events on the causal pathway to cancer. By identifying and deploying sensi-

tive biomarkers of carcinogenic exposure, susceptibility genes, and intermediate outcomes, it should be possible to more precisely define individuals at elevated risk of cancer, and to design and test novel approaches to diagnostic and preventive interventions.

This optimism is tempered, however, by the formidable challenges for epidemiologic and multidisciplinary research to identify, select, measure, validate, and integrate biomarkers that are predictive of cancer risk and amenable to preventive measures. While this book presents a wealth of information about cancer precursors, it also indicates the complexity of the task ahead for epidemiologists, as well as clinicians, molecular biologists, and other scientists, whose work on precursors may usher in new strategies to eliminate cancer before it develops and escapes control.

Joseph F. Fraumeni, Jr., MD, MSc
Director, Division of Cancer
Epidemiology and Genetics
National Cancer Institute
National Institutes of Health
Rockville, Maryland, USA

Preface

The purpose of this book is to bring together in one place reviews of the descriptive, analytical, and molecular epidemiological research on cancer precursors at specific anatomical locations, as well as a discussion of the methodological issues associated with the study of cancer precursors. We feel that such a book is particularly timely since the last few years have brought considerable progress in our understanding of the early natural history of cancer and of the etiology of precursor lesions. There have also been improvements in the means of detecting precursor lesions, either directly or via testing of surrogate biomarkers. While progress has perhaps been more rapid for cancer precursors at those anatomical sites which are more accessible and therefore more amenable to study, there is now a considerable body of knowledge bearing on the topic of precursor lesions at many sites.

The book is divided into five sections. Part I seeks to place subsequent chapters in context by providing brief overviews of the molecular basis of carcinogenesis and of the histological aspects of cancer precursors.

Part II addresses some of the issues related to the measurement, interpretation, and study of precursor lesions. Specifically, this section includes a chapter on the conceptual basis for studying precursor lesions, and on the practical aspects of obtaining, processing, and analyzing tissues containing either precancerous lesions or specimens enabling biomarkers of their presence to be detected. Intermediate markers (surrogate endpoints) have an increasingly important role to play in cancer research, and Part II also includes a chapter on the theoretical and practical problems involved in the use of surrogate endpoints in experimental and observational studies of cancer. The final chapter in this section discusses the assessment of epidemiologic relationships involving cancer precursors and the impact of measurement error on the study of such relationships.

The main section of the book, Part III, contains reviews of cancer precursors at the most important anatomical sites at which solid tumors occur. These reviews include discussion of the epidemiol-

ogy of these lesions, and where appropriate, aspects of their detection and prevention. Somewhat inevitably, the authors have taken different approaches in responding to their task, given that there are considerable between-site differences in the current state of knowledge and that much of the information regarding risk factors for cancer precursors overlaps with that available for invasive cancers of the same organ site.

Part IV includes chapters on various aspects of the control of cancer precursors. A chapter on screening addresses issues concerning the role of secondary prevention of cancer precursors, with particular emphasis on screening for precursors of cervix and colorectal cancer, for which the relevant concepts are most developed. A chapter on chemoprevention discusses the use of precancerous lesions and early associated biomarkers as surrogate endpoints to characterize cancer chemopreventive efficacy. The third chapter of this section summarizes evidence-based policy recommendations from different national and international agencies on screening and prevention, with particular emphasis on cancer precursors.

Part V, the final section of the book, contains a brief chapter in which we attempt to peer into the future to anticipate how research on the etiology, detection, and prevention of cancer precursors might develop.

The book includes contributions by well-established scientists who work on topics related to the biology, epidemiology, and control of cancer precursors, and these scientists have written their chapters in the knowledge that the target audience encompasses a broad professional base, including basic cancer researchers, epidemiologists, oncologists, molecular biologists, pathologists, health policy professionals, and graduate students in cancer-related fields. We thank the contributors for their superb efforts to make their chapters accessible to such a wide audience. We also appreciate their patience and diligence in revising their chapter manuscripts in response to our editorial requests to meet the common style and content structure that we attempted to impose upon the contributions within each section.

Our task was simplified enormously by the wonderful editorial staff at Springer-Verlag who shepherded us through the entire publication process. In particular, we thank Laura Gillan, Carol Wang, and Cindy Chang for their excellent support and responsiveness to all of the issues that we raised during the production of the book. We also thank Eliane Duarte-Franco, Elvira Rocco Ickowicz, Nicolas Schlecht, Anita Koushik, Jason Parente, Javier Pintos, Marie-Claude Rousseau Sarah Mitchell-Weed, and Candida Pizzolongo, for their superb assistance with valuable discussions, locating references, and other tasks associated with the writing and editing of the book. J. Baron (author of the chapter on colorectal lesions) received helpful advice and photomicrographs from Jeremy Bass and Daniel Longnecker. Grants NCI CA54053, CA63933, and PHS 5M01-RR-00079 provided support for the work of J. Palefsky (chapter on anal lesions). The latter acknowledges

the contributions of his collaborators in the UCSF anal neoplasia cohort study: Elizabeth Holly, Mary Ralston, Naomi Jay, Michael Berry, Maria Da Costa, and Teresa Darragh, and in the cost-effectiveness analysis study: Suzanne Goldie, Milton Weinstein, and Karen Kuntz. E. Franco's contributions were supported by a Distinguished Scientist Award from the Medical Research Council of Canada.

Finally, a short note on the history of this book. Over the last 11 years, the editors have collaborated closely on various projects on cancer epidemiology and prevention and on methodological issues related to error in the measurement of intermediate endpoints for cancer. The decision to jointly edit this book was taken about two years ago and was a natural consequence of this long-standing collaboration. Bringing this writing and editing project to bear fruit required more hours and exchanges of electronic mail messages and phone conversations than we care to count. The order of our names on the masthead reflects nothing other than a simple alphabetical listing. We both enjoyed producing this tome immensely, and we sincerely hope that the reader will find it a valuable resource.

Eduardo L. Franco
MPH, DrPH
Montreal, Quebec

Thomas E. Rohan
MB, BS, PhD
Bronx, New York

August 2001

Contributors

John A. Baron, MD, MS, MSc

Departments of Medicine and Community and Family Medicine,
Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA

Neil Caporaso, MD

Pharmacogenetic Section, Genetic Epidemiology Branch, Division
of Cancer Epidemiology and Genetics, National Cancer Institute,
National Institutes of Health, Rockville, MD 20892, USA

Michael B. Cohen, MD

Department of Pathology, University of Iowa, Iowa City, IA 52242-
1087, USA

Carlos Cordon-Cardo, MD

Department of Pathology, Division of Molecular Biology, Memorial
Sloan-Kettering Cancer Center, New York, NY 10021, USA

Pelayo Correa, MD

Department of Pathology, Louisiana State University Health Sci-
ences Center, New Orleans, LA 70112-1393, USA

Janet R. Daling, MD

Division of Public Health Sciences, Fred Hutchinson Cancer
Research Center, University of Washington, Seattle, WA 98109-1024,
USA

Alex Ferenczy, MD

Department of Pathology, Jewish General Hospital, Montreal,
Quebec H3T 1E2, Canada

Eduardo L. Franco, MPH, DR PH

Departments of Epidemiology and Oncology, Division of Cancer
Epidemiology, McGill University, Montreal, Quebec H2W 1S6,
Canada

Richard P. Gallagher, MD

Cancer Control Research Program, BC Cancer Agency, Vancouver,
British Columbia V5Z 4E6, Canada

Michael Goggins, MD

Departments of Pathology, Oncology, and Medicine, Johns
Hopkins Hospital, Baltimore, MD 21287, USA

Ralph H. Hruban, MD

Departments of Pathology and Oncology, Johns Hopkins Hospital,
Baltimore, MD 21287, USA

Christine Iacobuzio-Donahue, MD, PhD

Department of Pathology, Johns Hopkins Hospital, Baltimore, MD
21287, USA

Rita A. Kandel, MD

Department of Pathology and Laboratory Medicine, Mount Sinai
Hospital, Toronto, Ontario M5G 1X5, Canada

Gary J. Kelloff, MD

Division of Cancer Prevention, National Cancer Institute, National
Institutes of Health, Bethesda, MD 20892, USA

Tim K. Lee, MSc, PhD

Cancer Control Research Program, BC Cancer Agency, Vancouver,
British Columbia V5Z 4E6, Canada

Margaret M. Madeleine, MS, PhD

Department of Epidemiology, Program in Epidemiology, Fred
Hutchinson Cancer Research Center, University of Washington,
Seattle, WA 98109-1024, USA

Pamela M. Marcus, MS, PhD

Division of Cancer Prevention, National Cancer Institute, National
Institutes of Health, Bethesda, MD 20895-7354, USA

James R. Marshall, PhD

Arizona Cancer Center, University of Arizona, Tucson, AZ 85724,
USA

Anthony B. Miller, MB, ChB

Division of Clinical Epidemiology, Deutsches Krebsforschungzen-
trum, 69009 Heidelberg, Germany

Joel M. Palefsky, MD

Department of Laboratory Medicine, University of California, San
Francisco, San Francisco, CA 94143, USA

Kamal S. Pohar, MD

Department of Urology, Memorial Sloan-Kettering Cancer Center,
New York, NY 10021, USA

Thomas E. Rohan, MB, BS, PhD

Department of Epidemiology and Social Medicine, Albert Einstein
College of Medicine, Bronx, NY 10461, USA

R. Sankaranarayanan, MD

Unit of Descriptive Epidemiology, International Agency for
Research on Cancer, Lyon F-69372, France

Regina M. Santella, PhD

Division of Environmental Health Sciences, Mailman School of
Public Health of Columbia University, New York, NY 10032, USA

Arthur Schatzkin, MD, DrPH

Nutritional Epidemiology Branch, National Cancer Institute,
National Institutes of Health, Bethesda, MD 20892, USA

Joellen M. Schildkraut, PhD

Department of Community and Family Medicine, Cancer Preven-
tion, Detection, and Control Research Program, Duke University
Medical Center, Durham, NC 27710, USA

Morris Sherman, MB, BCh, PhD

Departments of Medicine and Pathology, University of Toronto,
Toronto General Hospital, Toronto, Ontario M5G 2C4, Canada

Caroline C. Sigman, PhD

CCS Associates, Mountain View, CA 94043, USA

Thara Somanathan, MD

Department of Pathology, Regional Cancer Center, Trivandrum
695011, India

Hisham K. Tamimi, MD

Departments of Epidemiology and Obstetrics and Gynecology,
Program in Epidemiology, Fred Hutchinson Cancer Research
Center, University of Washington, Seattle, WA 98109-1024, USA

William D. Travis, MD

Department of Pulmonary and Mediastinal Pathology, Armed
Forces Institute of Pathology, Washington, DC 20306-6000, USA

Thomas L. Vaughan, MD

Department of Epidemiology, Fred Hutchinson Cancer
Research Center, University of Washington, Seattle, WA 98109-
1024, USA

Jim Vaught, PhD

Division of Cancer Epidemiology and Genetics, Pharmacogenetic
Section, Genetic Epidemiology Branch, National Cancer Institute,
National Institutes of Health, Rockville, MD 20892, USA

Ian Wanless, MD

University of Toronto, Toronto General Hospital, Toronto, Ontario
M5G 2C4, Canada

David P. Wood, Jr., MD

Department of Urologic Oncology, Karmanos Cancer Institute,
Wayne State University, Harper Hospital, Detroit, MI, 48201, USA

Contents

Foreword, by <i>Joseph F. Fraumeni, Jr.</i>	vii
Preface	ix
Contributors	xvii

Introduction	1
<i>Thomas E. Rohan and Eduardo L. Franco</i>	

Part I Biological Basis of Carcinogenesis

1 Mechanisms and Biological Markers of Carcinogenesis	7
<i>Regina M. Santella</i>	
2 Morphology of Cancer Precursor Lesions	20
<i>Michael B. Cohen</i>	

Part II Issues Related to Measurement and Interpretation of Cancer Precursors

3 Collection, Processing, and Analysis of Preneoplastic Specimens	33
<i>Neil Caporaso and Jim Vaught</i>	
4 Intermediate Markers in Cancer Research: Theoretical and Practical Issues in the Use of Surrogate Endpoints	46
<i>Arthur Schatzkin</i>	
5 Assessing Epidemiological Relations and the Role of Measurement Errors	60
<i>Eduardo L. Franco and Thomas E. Rohan</i>	

Part III Site-Specific Precancerous Conditions

6	Upper Aerodigestive Tract	77
	<i>R. Sankaranarayanan and Thara Somanathan</i>	
7	Esophagus	96
	<i>Thomas L. Vaughan</i>	
8	Stomach	117
	<i>Pelayo Correa</i>	
9	Colon and Rectum	127
	<i>John A. Baron</i>	
10	Anus	151
	<i>Joel M. Palefsky</i>	
11	Liver	164
	<i>Morris Sherman and Ian Wanless</i>	
12	Pancreas	186
	<i>Ralph H. Hruban, Christine Iacobuzio-Donahue, and Michael Goggins</i>	
13	Lung	201
	<i>Pamela M. Marcus and William D. Travis</i>	
14	Skin	220
	<i>Richard P. Gallagher and Tim K. Lee</i>	
15	Breast	232
	<i>Thomas E. Rohan and Rita A. Kandel</i>	
16	Cervix	249
	<i>Eduardo L. Franco and Alex Ferenczy</i>	
17	Endometrium	287
	<i>Eduardo L. Franco and Alex Ferenczy</i>	
18	Ovary	304
	<i>Joellen M. Schildkraut</i>	
19	Vulva and Vagina	321
	<i>Margaret M. Madeleine, Janet R. Daling, and Hisham K. Tamimi</i>	
20	Prostate	333
	<i>James R. Marshall and David P. Wood, Jr.</i>	
21	Bladder	344
	<i>Kamal S. Pohar and Carlos Cordon-Cardo</i>	

Part IV Control of Cancer Precursors

22	Screening	365
	<i>Anthony B. Miller</i>	